Blood DNA Methylation Signature for Incident Dementia: Evidence from Longitudinal Cohorts
Abstract
INTRODUCTIONDistinguishing between molecular changes that precede dementia onset and those resulting from the disease is challenging with cross-sectional studies.
METHODSWe studied blood DNA methylation (DNAm) differences and incident dementia in two large longitudinal cohorts: the Offspring cohort of the Framingham Heart Study (FHS) and the Alzheimers Disease Neuroimaging Initiative (ADNI) study. We analyzed blood DNAm samples from over 1,000 cognitively unimpaired subjects.
RESULTSMeta-analysis identified 44 CpGs and 44 differentially methylated regions consistently associated with time to dementia in both cohorts. Our integrative analysis identified early processes in dementia, such as immune responses and metabolic dysfunction. Furthermore, we developed a Methylation-based Risk Score, which successfully predicted future cognitive decline in an independent validation set, even after accounting for age, sex, APOE {varepsilon}4, years of education, baseline diagnosis, and baseline MMSE score.
DISCUSSIONDNA methylation offers a promising source of biomarker for early detection of dementia.
The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.
Research summary
The paper investigates blood DNA methylation as a potential biomarker for early detection of dementia, which is an age-related disease. While it does not directly address the root causes of aging or lifespan extension, it contributes to understanding the biological processes associated with dementia, which is relevant to aging research. The findings are solid and provide a useful tool for predicting cognitive decline, but they do not represent a major breakthrough or transformative advancement in the field.
Author of this paper? Send a correction.